The Oral Medicine Clinic, Hollywood Private Hospital, Nedlands, Western Australia, Australia.
Anatomical Pathology, Australian Clinical Labs, Subiaco, Western Australia, Australia.
Aust Dent J. 2021 Sep;66(3):340-345. doi: 10.1111/adj.12833. Epub 2021 Mar 5.
Secukinumab (Cosentyx®) is an IL-17A inhibitor which is used for the management of psoriasis, active psoriatic arthritis or ankylosing spondylitis. Oral adverse events of secukinumab therapy are not widely appreciated. This article highlights the presentation of two concurrent oral adverse events of secukinumab therapy; namely chronic hyperplastic candidosis (CHC) and oral lichenoid lesion (OLL). This is the first documented case report of CHC occurring as a consequence of secukinumab therapy, and represents a new adverse effect which general and specialist oral health practitioners should be aware of. This case highlights the importance of correlating the presence of oral lesions with the patient's medical history, keeping up to date with the development of new medications and pharmacotherapeutics, having a deep understanding of underlying biological processes related to various oral diseases, and appreciating the use of clinical adjunctive devices. Accurate diagnosis is key to formulating a correct management plan.
司库奇尤单抗（Cosentyx®）是一种白细胞介素-17A 抑制剂，用于治疗银屑病、活动性银屑病关节炎或强直性脊柱炎。司库奇尤单抗治疗的口服不良反应尚未得到广泛认识。本文重点介绍了司库奇尤单抗治疗的两种同时发生的口服不良反应，即慢性增生性念珠菌病（CHC）和口腔扁平苔藓样病变（OLL）。这是首例因司库奇尤单抗治疗而发生 CHC 的有记录病例报告，代表了一种新的不良反应，普通和专业口腔健康从业者都应该对此有所了解。该病例强调了将口腔病变与患者的病史相关联、了解新药物和药物治疗的发展、深入了解与各种口腔疾病相关的潜在生物学过程以及认识临床辅助设备的重要性。准确的诊断是制定正确治疗计划的关键。
